Business Wire

Gemalto Brings Secure, Multi-Factor Authentication to Belgium’s Pioneering National Mobile Identity Scheme itsme®

Jaa

Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, has enabled Belgian mobile ID scheme itsme® to enroll 350,000 users and securely process one million transactions per month for both private and public online services – making it one of the most successful mobile ID applications in Europe within one year of launch. As well as bringing greater convenience to consumers, itsme® provides merchants, government, and financial institutions with strong, multi-factor authentication that is in line with PSD2, GDPR and is certified for eIDAS.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180604006232/en/

Digital ID for Belgian citizens Credit: istockphoto

Digital ID for Belgian citizens Credit: istockphoto

itsme® was developed by Belgian Mobile ID, a consortium of Belgium’s leading banks and mobile network operators, in close collaboration with Gemalto. It has been officially recognized by the Belgian government as a way for citizens to connect to numerous online public services, including taxation, pensions and health, as well as online banking and mobile operator services. In its first year the app is already being used widely, with the average user completing six banking transactions and three e-Government transactions each month.

In an increasingly digital world with growing numbers of government services moving online, a secure digital identity scheme allows consumers to prove who they are. The itsme® app allows users to create a 100% verifiable ID to safely and easily confirm their identity and approve transactions with their mobile phone, meaning they can access services on-the-go with one single login. The seamless service grants access to a wide portfolio of services, including those related to telecoms, financials, HR, and health, without having to fill in a time-consuming form each time. itsme® will also provide users in the near future with a qualified e-signature that is the legal equivalent of a handwritten signature, which they can use to easily sign documents.

Following many years of collaboration in the fields of banking and mobile payment security, Belgian Mobile ID tasked Gemalto with providing robust, end-to-end security for the itsme® app. Gemalto’s strong mobile authentication solution, using the latest biometric technology combined with digital identity expertise, provides the highest level of security for users to access services, confirm transactions and sign for private and government online applications. As a result, users stay in control of their data, managing privacy in a secure environment that protects them from fraud and security breaches.

Kris de Ryck, CEO, Belgian Mobile ID, commented, “The itsme® app is a significant milestone on the digital roadmap of Belgium and we could not have done it without Gemalto. Our partnership helps us provide a truly innovative and 100% secure approach to accessing online services. While Belgian citizens are leading the world in embracing technology in this Mobile Identity scheme, we hope our partnership will be an example for other countries in Europe to provide seamless and secure connections to online public services with itsme®.”

Philippe Vallée, CEO, Gemalto, added, “In an increasingly digital world the need for stronger and more trusted digital identities is growing. We know that consumers want their data to be secure, but they also want a painless and hassle-free experience when accessing online services. We hope that this is just the start and that further cooperation in this field will lead to more schemes providing a seamless online experience for everyone in Europe across many different sectors.”

Gemalto CEO Philippe Vallée and Kris De Ryck, CEO of Belgian Mobile ID, will be speaking on the topic of Digital identity at Money 20/20 in Amsterdam, on 5 June at 11.50am on the High Wire Stage.

In addition, stop by stand B50 to discover itsme® in action and to hear more about the latest innovations from Gemalto that can help your brand capitalize on existing and new technologies while ensuring simple, secure and enjoyable customer journeys.

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security, with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com, or follow @gemalto on Twitter.

Contact information

Gemalto media:
Tauri Cox, +1 512 257 3916
North America
tauri.cox@gemalto.com
or
Sophie Dombres, +33 4 42 36 57 38
Europe Middle East & Africa
or
sophie.dombres@gemalto.com
Jaslin Huang, +65 6317 3005
Asia Pacific
jaslin.huang@gemalto.com
or
Enriqueta Sedano, +52 5521221422
Latin America
enriqueta.sedano@gemalto.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme